Pfizer Forecasts Q4 EPS at $0.57, Licenses Matrix-M, Faces Patent Cliffs
Analysts forecast Pfizer's Q4 EPS at $0.57 versus $0.63 and revenue of $16.83 billion versus $17.76 billion after licensing its Matrix-M adjuvant to Novavax. Meanwhile, Pfizer faces three 2026 headwinds: trailing in GLP-1 weight-loss pipeline, patent cliffs for Ibrance (2027) and Eliquis/Vyndaqel (2028), and a dividend payout near 100% raising cut risk.
1. Lagging in the GLP-1 Weight-Loss Drug Market
Pfizer is entering 2026 well behind competitors in the rapidly expanding GLP-1 weight-loss segment. While market leaders have secured first-mover advantages and established extensive prescribing networks, Pfizer’s recently acquired weight-management asset faces a lengthy regulatory review and limited formulary access. Industry analysts project global GLP-1 sales could exceed $50 billion by 2027, and Pfizer’s delayed launch risks ceding significant market share and recurring revenue streams.
2. Upcoming Patent Expirations Threaten Blockbuster Revenue
Pfizer’s top-selling drugs Ibrance, Eliquis and Vyndaqel are set to lose exclusivity between 2027 and 2028, exposing the company to steep generic erosion. Ibrance sales, which generated more than $6.5 billion in 2023, could decline by up to 80% within 12 months of patent expiry, according to industry forecasts. Similarly, combined sales of Eliquis and Vyndaqel—totaling nearly $12 billion last year—face biosimilar and generic competition, placing significant pressure on Pfizer’s overall top-line growth.
3. Dividend Payout Ratio Nears Unsustainable Levels
Pfizer’s dividend payout ratio is approaching 100%, driven by slowing post-pandemic sales and increased R&D spending. With annual dividend per share at $1.72 and consensus EPS forecasts dipping below $0.60 for Q4 2025, the company may struggle to maintain its current distribution level. Conservative income investors are voicing concerns that without a rebound in core product revenue or successful pipeline launches, Pfizer may be forced to cut its dividend or reduce the growth rate in the coming fiscal year.
4. Q4 Earnings Expectations Point to Revenue and Profit Declines
Analysts anticipate Pfizer will report fourth-quarter EPS of $0.57, down from $0.63 in the prior year, with revenues of $16.83 billion versus $17.76 billion a year earlier. This forecast reflects waning demand for pandemic-related products and slower uptake of new assets. On January 20, Pfizer signed a license agreement with Novavax for Matrix-M adjuvant use, a move expected to bolster vaccine R&D but unlikely to offset near-term revenue headwinds. Ahead of the February 3 earnings release, several leading analysts have revised their forecasts downward, underscoring investor caution about Pfizer’s growth outlook.